Susan Halabi | Scholars@Duke

Susan Halabi
Professor of Biostatistics and Bioinformatics

Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.

Current Appointments & Affiliations

Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2012
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1996

Contact Information

2424 Erwin Road 11th Floor, 11088 Hock Plaza, Durham, NC 27705
Duke Box 2717, Durham, NC 27710
susan.halabi@duke.edu (919) 681-5430
Prostate Cancer Nomograms for Predicting Overall Survival
curriculum vitae

Background
Education, Training, & Certifications
- Ph.D., University of Texas Health Sciences Center at Houston 1994
Duke Appointment History
- Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2005 - 2012
- Associate Professor in Surgery, Surgery, Urology, Surgery 2008 - 2011
- Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2000 - 2005
- Assistant Professor in Community and Family Medicine, Family Medicine and Community Health, Clinical Science Departments 1997 - 2000
- Instructor, Temporary in the Department of Community and Family Medicine, Family Medicine and Community Health, Clinical Science Departments 1996 - 1997
Recognition
In the News
- JUN 4, 2018 Duke Health News
  
  Survival Benefit for African-Americans with Advanced Prostate Cancer
- MAR 9, 2016 Stat News
  
  When prostate cancer spreads, where it goes matters
- MAR 8, 2016
  
  Where Prostate Cancer Spreads In the Body Affects Survival Time
- OCT 20, 2013
  
  New prognostic model predicts survival in advanced prostate cancer
Awards & Honors
Expertise
Subject Headings
Global Scholarship
- Research
  - Peru (Country)
Research
Selected Grants
- Duke CTSA (KL2) awarded by National Institutes of Health 2018 - 2023
- Duke CTSA (TL1) awarded by National Institutes of Health 2018 - 2023
- Role of oncogenic phosphorylated MED1 in aggressive prostate cancer awarded by National Institutes of Health 2017 - 2022
- PCRP Clinical Consortium: Duke University Clinical Research Site awarded by Department of Defense 2007 - 2021
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer awarded by Department of Defense 2018 - 2021
- Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2021
- Surrogate Endpoints of Overall Survival in Men with Metastatic Hormone Sensitive Prostate Cancer awarded by Prostate Cancer Foundation 2018 - 2020
- Health Disparity in African Americans: A Meta-analysis of Six Phase III Trials in Metastatic Castration-Resistant Prosta awarded by Department of Defense 2015 - 2019
- Precision Medicine in Platinum-treated Lethal Bladder Cancer awarded by Memorial Sloan Kettering Cancer Center 2017 - 2019
- Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) awarded by Prostate Cancer Foundation 2014 - 2019
- Serum Androgens and Survival in CRPC awarded by University of California - San Francisco 2015 - 2018
- Admin Suppl to Study Mechanisms of Ca Sensitivity and Resistance... CALGB 90203 awarded by Brigham and Women's Hospital 2016 - 2018
- Optimizing First Line Treatment for Men with Castrate Resistant Prostate Cancer awarded by Prostate Cancer Foundation 2015 - 2018
- National Clinical Trials Network - Network Group Statistics and DMCs awarded by Mayo Clinic 2014 - 2017
- Validation of prognostic and pathway signatures in lethal prostate cancer awarded by National Institutes of Health 2011 - 2017
- Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer awarded by National Institutes of Health 2011 - 2016
- Expression Profiling of Renal Cell Carcinoma Utilizing Tissue from CALGB 90206 awarded by Cedars Sinai Medical Center 2012 - 2015
- Predictive Markers in Metastatic Renal Cancer awarded by University of California - San Francisco 2013 - 2014
- Cancer and Leukemia Group B Statistical Center awarded by National Institutes of Health 1982 - 2010
- Telomerase RNA Transfected Dendritic Cell Vaccines awarded by National Institutes of Health 2002 - 2006
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Ryan, Charles J., Sandipan Dutta, William K. Kelly, Carly Russell, Eric J. Small, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi, and Susan From The Alliance for Clinical Trials in Oncology Genitourinary Committee. “Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)..” Prostate Cancer Prostatic Dis, May 3, 2019. https://doi.org/10.1038/s41391-019-0152-3.
    Full Text Link to Item
  - Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, et al. “Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study..” J Clin Oncol 37, no. 13 (May 1, 2019): 1120–29. https://doi.org/10.1200/JCO.18.01731.
    Full Text Link to Item
  - Sugimoto, Tomoyuki, Toshimitsu Hamasaki, Scott R. Evans, and Susan Halabi. “Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes..” Lifetime Data Analysis, April 12, 2019. https://doi.org/10.1007/s10985-019-09470-4.
    Full Text
  - Tierney, Jayne F., Claire L. Vale, Wendy R. Parelukar, Larysa Rydzewska, and Susan Halabi. “Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer..” European Urology Focus 5, no. 2 (March 2019): 137–43. https://doi.org/10.1016/j.euf.2019.01.005.
    Full Text
  - Halabi, Susan, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Ian M. Thompson, Kim N. Chi, et al. “Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 37, no. 5 (February 2019): 403–10. https://doi.org/10.1200/jco.18.01279.
    Full Text
  - Ma, Hua, Susan Halabi, and Aiyi Liu. “On the use of min-max combination of biomarkers to maximize the partial area under the ROC curve..” J Probab Stat 2019 (2019). https://doi.org/10.1155/2019/8953530.
    Full Text Link to Item
  - Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]..” European Journal of Cancer (Oxford, England : 1990) 103 (November 2018). https://doi.org/10.1016/j.ejca.2018.09.022.
    Full Text
  - Mohler, James L., Susan Halabi, Stephen T. Ryan, Ali Al-Daghmin, Mitchell H. Sokoloff, Gary D. Steinberg, Ben L. Sanford, et al. “Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series..” Prostate Cancer Prostatic Dis, November 1, 2018. https://doi.org/10.1038/s41391-018-0106-1.
    Full Text Link to Item
  - Li, Megan, Flora Mulkey, Chen Jiang, Bert H. O’Neil, Bryan P. Schneider, Fei Shen, Paula N. Friedman, et al. “Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24, no. 19 (October 2018): 4734–44. https://doi.org/10.1158/1078-0432.ccr-17-1523.
    Full Text
  - Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update..” European Journal of Cancer (Oxford, England : 1990) 94 (May 2018): 115–25. https://doi.org/10.1016/j.ejca.2018.02.012.
    Full Text
  - Anderson, Kenneth, Nofisat Ismaila, Patrick J. Flynn, Susan Halabi, Sundar Jagannath, Mohammed S. Ogaily, Jim Omel, et al. “Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 8 (March 2018): 812–18. https://doi.org/10.1200/jco.2017.76.6402.
    Full Text
  - Gillessen, Silke, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Alberto Bossi, Rob Bristow, Brett Carver, et al. “Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017..” Eur Urol 73, no. 2 (February 2018): 178–211. https://doi.org/10.1016/j.eururo.2017.06.002.
    Full Text Link to Item
  - “Editorial Board for The 2015 International Society for Biopharmaceutical Statistics (ISBS) and DIA China Special Issue.” Statistics in Biopharmaceutical Research 10, no. 1 (January 2, 2018): 70–70. https://doi.org/10.1080/19466315.2018.1451706.
    Full Text
  - Armstrong, A. J., E. S. Antonarakis, M. -. E. Taplin, W. K. Kelly, H. Beltran, K. Fizazi, W. L. Dahut, et al. “Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet..” Ann Oncol 29, no. 1 (January 1, 2018): 23–25. https://doi.org/10.1093/annonc/mdx648.
    Full Text Link to Item
  - Mangat, Pam K., Susan Halabi, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A. Janeway, Philip J. Stella, et al. “Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study..” Jco Precision Oncology 2018 (January 2018). https://doi.org/10.1200/po.18.00122.
    Full Text
  - Pi, Lira, and Susan Halabi. “Combined Performance of Screening and Variable Selection Methods in Ultra-High Dimensional Data in Predicting Time-To-Event Outcomes..” Diagnostic and Prognostic Research 2 (January 2018). https://doi.org/10.1186/s41512-018-0043-4.
    Full Text
  - Mahar, Alyson L., Carolyn Compton, Susan Halabi, Kenneth R. Hess, Martin R. Weiser, and Patti A. Groome. “Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes..” Journal of Surgical Oncology 116, no. 8 (December 2017): 969–82. https://doi.org/10.1002/jso.24774.
    Full Text
  - Xie, Wanling, Meredith M. Regan, Marc Buyse, Susan Halabi, Philip W. Kantoff, Oliver Sartor, Howard Soule, et al. “Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer..” J Clin Oncol 35, no. 27 (September 20, 2017): 3097–3104. https://doi.org/10.1200/JCO.2017.73.9987.
    Full Text Link to Item
  - Armstrong, Andrew J., Susan Halabi, Patrick Healy, Joshi J. Alumkal, Carolyn Winters, Julie Kephart, Rhonda L. Bitting, et al. “Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.” European Journal of Cancer 81 (August 2017): 228–36. https://doi.org/10.1016/j.ejca.2017.02.030.
    Full Text Link to Item
  - Choueiri, Toni K., Susan Halabi, Michael J. Morris, and Daniel George. “Reply to B. Rini et al and S. Buti et al..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 16 (June 2017): 1859–60. https://doi.org/10.1200/jco.2017.72.2629.
    Full Text
  - Armstrong, Andrew J., Michael S. Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R. Harrison, et al. “Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.” Prostate 77, no. 4 (March 1, 2017): 385–95. https://doi.org/10.1002/pros.23277.
    Full Text Link to Item
  - Choueiri, Toni K., Susan Halabi, Ben L. Sanford, Olwen Hahn, M Dror Michaelson, Meghara K. Walsh, Darren R. Feldman, et al. “Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial..” J Clin Oncol 35, no. 6 (February 20, 2017): 591–97. https://doi.org/10.1200/JCO.2016.70.7398.
    Full Text Link to Item
  - Zhang, Qiang, Boris Freidlin, Edward L. Korn, Susan Halabi, Sumithra Mandrekar, and James J. Dignam. “Comparison of futility monitoring guidelines using completed phase III oncology trials..” Clinical Trials (London, England) 14, no. 1 (February 2017): 48–58. https://doi.org/10.1177/1740774516666502.
    Full Text
  - Lin, Chen-Yen, and Susan Halabi. “A Simple Method for Deriving the Confidence Regions for the Penalized Cox's Model via the Minimand Perturbation..” Communications in Statistics: Theory and Methods 46, no. 10 (January 2017): 4791–4808. https://doi.org/10.1080/03610926.2015.1085568.
    Full Text
  - Hertz, Daniel L., Kouros Owzar, Sherrie Lessans, Claudia Wing, Chen Jiang, William Kevin Kelly, Jai Patel, et al. “Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 22, no. 19 (October 2016): 4890–4900. https://doi.org/10.1158/1078-0432.CCR-15-2823.
    Full Text
  - Kattan, Michael W., Kenneth R. Hess, Mahul B. Amin, Ying Lu, Karl G. M. Moons, Jeffrey E. Gershenwald, Phyllis A. Gimotty, et al. “American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine..” Ca Cancer J Clin 66, no. 5 (September 2016): 370–74. https://doi.org/10.3322/caac.21339.
    Full Text Link to Item
  - Mahar, Alyson L., Carolyn Compton, Susan Halabi, Kenneth R. Hess, Jeffrey E. Gershenwald, Richard A. Scolyer, and Patti A. Groome. “Critical Assessment of Clinical Prognostic Tools in Melanoma..” Ann Surg Oncol 23, no. 9 (September 2016): 2753–61. https://doi.org/10.1245/s10434-016-5212-5.
    Full Text Link to Item
  - McEwen, Abigail R., Heileen Hsu-Kim, Nicholas A. Robins, Nicole A. Hagan, Susan Halabi, Olivo Barras, Daniel deB Richter, and John J. Vandenberg. “Residential metal contamination and potential health risks of exposure in adobe brick houses in Potosí, Bolivia..” The Science of the Total Environment 562 (August 2016): 237–46. https://doi.org/10.1016/j.scitotenv.2016.03.152.
    Full Text
  - Halabi, Susan, William Kevin Kelly, Hua Ma, Haojin Zhou, Nicole C. Solomon, Karim Fizazi, Catherine M. Tangen, et al. “Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer..” J Clin Oncol 34, no. 14 (May 10, 2016): 1652–59. https://doi.org/10.1200/JCO.2015.65.7270.
    Full Text Link to Item
  - Scher, Howard I., Michael J. Morris, Walter M. Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, et al. “Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3..” J Clin Oncol 34, no. 12 (April 20, 2016): 1402–18. https://doi.org/10.1200/JCO.2015.64.2702.
    Full Text Link to Item
  - Armstrong, A. J., P. Healy, S. Halabi, R. Vollmer, A. Lark, G. Kemeny, K. Ware, and S. J. Freedland. “Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer..” Prostate Cancer and Prostatic Diseases 19, no. 1 (March 2016): 40–45. https://doi.org/10.1038/pcan.2015.46.
    Full Text Open Access Copy
  - Armstrong, A. J., S. Halabi, P. Healy, W. R. Lee, B. F. Koontz, J. W. Moul, K. Mundy, et al. “A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.” Prostate Cancer and Prostatic Diseases 19, no. 1 (March 2016): 100–106. https://doi.org/10.1038/pcan.2015.59.
    Full Text Link to Item
  - Armstrong, Andrew J., Susan Halabi, Tim Eisen, Samuel Broderick, Walter M. Stadler, Robert J. Jones, Jorge A. Garcia, et al. “Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial..” The Lancet. Oncology 17, no. 3 (March 2016): 378–88. https://doi.org/10.1016/s1470-2045(15)00515-x.
    Full Text
  - Kim, Sangjin, and Susan Halabi. “High Dimensional Variable Selection with Error Control..” Biomed Research International 2016 (January 2016). https://doi.org/10.1155/2016/8209453.
    Full Text Open Access Copy
  - ICECaP Working Group, E. J., Christopher Sweeney, Mari Nakabayashi, Meredith Regan, Wanling Xie, Julia Hayes, Nancy Keating, et al. “The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)..” Journal of the National Cancer Institute 107, no. 12 (December 2015). https://doi.org/10.1093/jnci/djv261.
    Full Text
  - Kim, Hyung L., Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew B. Nixon, Eric J. Small, et al. “A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)..” Ebiomedicine 2, no. 11 (November 2015): 1814–20. https://doi.org/10.1016/j.ebiom.2015.09.012.
    Full Text Link to Item
  - Mahar, Alyson L., Carolyn Compton, Lisa M. McShane, Susan Halabi, Hisao Asamura, Ramon Rami-Porta, Patti A. Groome, and Patti A. Molecular Modellers Working Group of American Joint Committee on Cancer. “Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 10, no. 11 (November 2015): 1576–89. https://doi.org/10.1097/JTO.0000000000000652.
    Full Text
  - Gillessen, S., A. Omlin, G. Attard, J. S. de Bono, E. Efstathiou, K. Fizazi, S. Halabi, et al. “Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015..” Ann Oncol 26, no. 8 (August 2015): 1589–1604. https://doi.org/10.1093/annonc/mdv257.
    Full Text Link to Item
  - Potthoff, Richard F., and Susan Halabi. “A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events..” Pharmaceutical Statistics 14, no. 4 (July 2015): 273–83. https://doi.org/10.1002/pst.1683.
    Full Text
  - Becker, Andreas, Christian Eichelberg, and Maxine Sun. “Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?.” Cancer 121, no. 11 (June 2015): 1906–7. https://doi.org/10.1002/cncr.29255.
    Full Text
  - Hagan, Nicole, Nicholas Robins, Heileen Hsu-Kim, Susan Halabi, Ruben Dario Espinoza Gonzales, Enrique Ecos, Daniel Richter, and John Vandenberg. “Mercury hair levels and factors that influence exposure for residents of Huancavelica, Peru..” Environmental Geochemistry and Health 37, no. 3 (June 2015): 507–14. https://doi.org/10.1007/s10653-014-9665-9.
    Full Text
  - Halabi, Susan, Brian I. Rini, Bernard Escudier, Walter M. Stadler, and Eric J. Small. “Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?.” Cancer 121, no. 11 (June 2015). https://doi.org/10.1002/cncr.29252.
    Full Text
  - Armstrong, Andrew J., and Susan Halabi. “Making progress on progression in metastatic prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 12 (April 2015): 1322–24. https://doi.org/10.1200/jco.2014.59.4283.
    Full Text
  - Patel, Jai N., Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, et al. “Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)..” Cancer 121, no. 7 (April 2015): 1025–31. https://doi.org/10.1002/cncr.29169.
    Full Text
  - Bitting, R. L., P. Healy, S. Halabi, D. J. George, M. Goodin, and A. J. Armstrong. “Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.” Urologic Oncology: Seminars and Original Investigations 33, no. 3 (March 1, 2015): 110.e1-110.e9. https://doi.org/10.1016/j.urolonc.2014.09.002.
    Full Text
  - Bitting, Rhonda L., Patrick Healy, Susan Halabi, Daniel J. George, Michael Goodin, and Andrew J. Armstrong. “Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer..” Urol Oncol 33, no. 3 (March 2015): 110.e1-110.e9. https://doi.org/10.1016/j.urolonc.2014.09.002.
    Full Text Link to Item
  - Sartor, Oliver, and Susan Halabi. “Independent data monitoring committees: an update and overview..” Urologic Oncology 33, no. 3 (March 2015): 143–48. https://doi.org/10.1016/j.urolonc.2014.12.013.
    Full Text
  - Sartor, Oliver, and Susan Halabi. “Independent data monitoring committees: An update and overview.” Urologic Oncology Seminars and Original Investigations 33, no. 3 (March 2015): 143–48. https://doi.org/10.1016/j.urolonc.2014.12.013.
    Full Text Link to Item
  - Moser, Barry Kurt, and Susan Halabi. “Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome..” Communications in Statistics: Theory and Methods 44, no. 2 (January 2015): 275–85. https://doi.org/10.1080/03610926.2012.705940.
    Full Text
  - Smith, Matthew R., Susan Halabi, and Eric J. Small. “Reply to F. Valcamonico et al..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 32 (November 2014). https://doi.org/10.1200/jco.2014.57.3808.
    Full Text
  - Halabi, S., H. Zhou, E. J. Small, N. C. Solomon, A. J. Armstrong, L. Shen, S. Oudard, O. Sartor, and J. S. de Bono. “795PA PROGNOSTIC MODEL FOR PREDICTING RADIOGRAPHIC PROGRESSION- FREE SURVIVAL (RPFS) IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER MEN TREATED WITH SECOND-LINE CHEMOTHERAPY..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 25, no. suppl_4 (September 2014).
  - Liu, C., A. Liu, J. Hu, V. Yuan, and S. Halabi. “Adjusting for misclassification in a stratified biomarker clinical trial.” Statistics in Medicine 33, no. 18 (August 15, 2014): 3100–3113. https://doi.org/10.1002/sim.6164.
    Full Text
  - Liu, Chunling, Aiyi Liu, Jiang Hu, Vivian Yuan, and Susan Halabi. “Adjusting for misclassification in a stratified biomarker clinical trial..” Statistics in Medicine 33, no. 18 (August 2014): 3100–3113. https://doi.org/10.1002/sim.6164.
    Full Text
  - “ERRATA.” Journal of Clinical Oncology 32, no. 13 (May 2014): 1387–1387. https://doi.org/10.1200/jco.2014.56.5366.
    Full Text
  - Smith, Matthew R., Susan Halabi, Charles J. Ryan, Arif Hussain, Nicholas Vogelzang, Walter Stadler, Ralph J. Hauke, et al. “Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)..” J Clin Oncol 32, no. 11 (April 10, 2014): 1143–50. https://doi.org/10.1200/JCO.2013.51.6500.
    Full Text Link to Item
  - Halabi, S. “Erratum.” Jnci Journal of the National Cancer Institute 106, no. 4 (April 8, 2014): dju096–dju096. https://doi.org/10.1093/jnci/dju096.
    Full Text
  - Halabi, Susan, Chen-Yen Lin, W Kevin Kelly, Karim S. Fizazi, Judd W. Moul, Ellen B. Kaplan, Michael J. Morris, and Eric J. Small. “Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer..” J Clin Oncol 32, no. 7 (March 1, 2014): 671–77. https://doi.org/10.1200/JCO.2013.52.3696.
    Full Text Link to Item
  - Halabi, Susan, Brian Rini, Bernard Escudier, Walter M. Stadler, and Eric J. Small. “Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma..” Cancer 120, no. 1 (January 2014): 52–60. https://doi.org/10.1002/cncr.28221.
    Full Text
  - Armstrong, A. J., T. Shen, S. Halabi, G. Kemeny, R. L. Bitting, P. Kartcheske, E. Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.” Clinical Genitourinary Cancer 11, no. 4 (December 1, 2013): 397–406. https://doi.org/10.1016/j.clgc.2013.05.007.
    Full Text
  - Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda L. Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer..” Clinical Genitourinary Cancer 11, no. 4 (December 2013): 397–406. https://doi.org/10.1016/j.clgc.2013.05.007.
    Full Text
  - Halabi, Susan, Andrew J. Armstrong, Oliver Sartor, Johann de Bono, Ellen Kaplan, Chen-Yen Lin, Nicole C. Solomon, and Eric J. Small. “Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy..” J Clin Oncol 31, no. 31 (November 1, 2013): 3944–50. https://doi.org/10.1200/JCO.2013.50.3201.
    Full Text Link to Item
  - Halabi, Susan, Chen-Yen Lin, Eric J. Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Petrylak, Cora N. Sternberg, et al. “Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy..” Journal of the National Cancer Institute 105, no. 22 (November 2013): 1729–37. https://doi.org/10.1093/jnci/djt280.
    Full Text
  - Lin, Chen-Yen, and Susan Halabi. “On model specification and selection of the Cox proportional hazards model..” Statistics in Medicine 32, no. 26 (November 2013): 4609–23. https://doi.org/10.1002/sim.5876.
    Full Text
  - Aggarwal, Rahul, Susan Halabi, William Kevin Kelly, Daniel George, John F. Mahoney, Frederick Millard, Walter M. Stadler, et al. “The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)..” Cancer 119, no. 20 (October 2013): 3636–43. https://doi.org/10.1002/cncr.28285.
    Full Text
  - Apolo, Andrea B., Irina Ostrovnaya, Susan Halabi, Alexia Iasonos, George K. Philips, Jonathan E. Rosenberg, Jamie Riches, Eric J. Small, Matthew I. Milowsky, and Dean F. Bajorin. “Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy.” Jnci: Journal of the National Cancer Institute 105, no. 7 (April 3, 2013): 499–503. https://doi.org/10.1093/jnci/djt015.
    Full Text
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Reply to M A Khattak et al..” J Clin Oncol 31, no. 7 (March 1, 2013): 972–73. https://doi.org/10.1200/JCO.2012.47.7224.
    Full Text Link to Item
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Reply to M A Khattak et al..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 7 (March 2013): 972–73. https://doi.org/10.1200/jco.2012.47.7224.
    Full Text
  - Lin, C. Y., E. J. Small, A. J. Armstrong, E. B. Kaplan, D. P. Petrylak, C. N. Sternberg, L. Shen, S. Oudard, J. S. De Bono, and A. O. Sartor. “A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013).
  - Aggarwal, R., S. Halabi, W. K. Kelly, D. George, J. F. Mahoney, F. Millard, W. M. Stadler, et al. “The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).” Cancer 119, no. 20 (2013): 3636–43. https://doi.org/10.1002/cncr.28285.
    Full Text
  - Hagan, Nicole, Nicholas Robins, Heileen Hsu-Kim, Susan Halabi, Ruben Dario Espinoza Gonzales, Daniel deB Richter, and John Vandenberg. “Residential mercury contamination in adobe brick homes in Huancavelica, Peru..” Plos One 8, no. 9 (January 2013). https://doi.org/10.1371/journal.pone.0075179.
    Full Text
  - Lin, C. Y., and S. Halabi. “On model specification and selection of the Cox proportional hazards model.” Statistics in Medicine 32, no. 26 (2013): 4609–23. https://doi.org/10.1002/sim.5876.
    Full Text
  - Atkinson, Thomas M., Susan Halabi, Antonia V. Bennett, Lauren Rogak, Laura Sit, Yuelin Li, Ellen Kaplan, Ethan Basch, and Ethan Cancer and Leukemia Group B. “Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903..” Pain Medicine (Malden, Mass.) 13, no. 11 (November 2012): 1417–24. https://doi.org/10.1111/j.1526-4637.2012.01498.x.
    Full Text
  - Armstrong, Andrew J., Daniel J. George, and Susan Halabi. “Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 27 (September 2012): 3402–7. https://doi.org/10.1200/jco.2011.40.9631.
    Full Text
  - Monk, J Paul, Susan Halabi, Joel Picus, Arif Hussain, George Philips, Ellen Kaplan, Tim Ahles, et al. “Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782..” Cancer 118, no. 17 (September 2012): 4139–47. https://doi.org/10.1002/cncr.26732.
    Full Text
  - Robins, Nicholas A., Nicole Hagan, Susan Halabi, Heileen Hsu-Kim, Ruben Dario Espinoza Gonzales, Mark Morris, George Woodall, et al. “Estimations of historical atmospheric mercury concentrations from mercury refining and present-day soil concentrations of total mercury in Huancavelica, Peru..” The Science of the Total Environment 426 (June 2012): 146–54. https://doi.org/10.1016/j.scitotenv.2012.03.082.
    Full Text
  - Halabi, Susan. “Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints..” Journal of Biometrics & Biostatistics 7 (May 2012). https://doi.org/10.4172/2155-6180.S7-015.
    Full Text
  - Kelly, William Kevin, Susan Halabi, Michael Carducci, Daniel George, John F. Mahoney, Walter M. Stadler, Michael Morris, et al. “Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 13 (May 2012): 1534–40. https://doi.org/10.1200/JCO.2011.39.4767.
    Full Text
  - Atkinson, Thomas M., Eric J. Small, Lauren Rogak, Laura Sit, Natalie Barragan, Mary Shaw, Liora Pollick, et al. “MEASUREMENT OF AFFECTIVE AND ACTIVITY PAIN INTERFERENCE USING THE BRIEF PAIN INVENTORY.” Annals of Behavioral Medicine 43 (April 1, 2012): S222–S222.
    Link to Item
  - Armstrong, Andrew J., Mario A. Eisenberger, Susan Halabi, Stephane Oudard, David M. Nanus, Daniel P. Petrylak, A Oliver Sartor, and Howard I. Scher. “Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer..” European Urology 61, no. 3 (March 2012): 549–59. https://doi.org/10.1016/j.eururo.2011.11.009.
    Full Text
  - Harzstark, Andrea Lynne, Susan Halabi, William Kevin Kelly, Michael J. Morris, Phillip G. Febbo, and Eric Jay Small. “Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy..” Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 129–129. https://doi.org/10.1200/jco.2012.30.5_suppl.129.
    Full Text
  - Halabi, S., W. K. Kelly, E. B. Kaplan, and E. J. Small. “Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Harzstark, A. L., S. Halabi, W. K. Kelly, M. J. Morris, P. G. Febbo, and E. J. Small. “Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Korn, Edward L., Boris Freidlin, Jeffrey S. Abrams, and Susan Halabi. “Design issues in randomized phase II/III trials..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 6 (February 2012): 667–71. https://doi.org/10.1200/JCO.2011.38.5732.
    Full Text
  - Moser, Barry Kurt, and Susan Halabi. “Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease..” Statistics in Medicine 31, no. 1 (January 2012): 29–44. https://doi.org/10.1002/sim.4414.
    Full Text
  - Hurwitz, Mark D., Susan Halabi, Laura Archer, Lamar S. McGinnis, Michael R. Kuettel, Steven J. DiBiase, and Eric J. Small. “Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809..” Cancer 117, no. 24 (December 2011): 5579–88. https://doi.org/10.1002/cncr.26203.
    Full Text
  - Liu, C., A. Liu, and S. Halabi. “A min-max combination of biomarkers to improve diagnostic accuracy.” Statistics in Medicine 30, no. 27 (November 30, 2011). https://doi.org/10.1002/sim.4317.
    Full Text
  - Liu, Chunling, Aiyi Liu, and Susan Halabi. “A min-max combination of biomarkers to improve diagnostic accuracy..” Statistics in Medicine 30, no. 16 (July 2011): 2005–14. https://doi.org/10.1002/sim.4238.
    Full Text
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).
  - Halabi, S., W. K. Kelly, D. J. George, M. J. Morris, E. B. Kaplan, and E. J. Small. “Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC)..” Journal of Clinical Oncology 29, no. 7_suppl (March 2011): 189–189. https://doi.org/10.1200/jco.2011.29.7_suppl.189.
    Full Text
  - Halabi, S., W. K. Kelly, D. J. George, M. J. Morris, E. B. Kaplan, and E. J. Small. “Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011).
  - Shapiro, C. L., S. Halabi, V. Hars, L. Archer, D. Weckstein, J. Kirshner, W. Sikov, et al. “Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809..” European Journal of Cancer (Oxford, England : 1990) 47, no. 5 (March 2011): 683–89. https://doi.org/10.1016/j.ejca.2010.11.024.
    Full Text
  - Picus, Joel, Susan Halabi, W Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter M. Stadler, Eric J. Small, and Eric J. Cancer and Leukemia Group B. “A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006..” Cancer 117, no. 3 (February 1, 2011): 526–33. https://doi.org/10.1002/cncr.25421.
    Full Text Link to Item
  - Hagan, N., N. Robins, H. Hsu-Kim, S. Halabi, M. Morris, G. Woodall, T. Zhang, A. Bacon, D. D. B. Richter, and J. Vandenberg. “Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia.” Atmospheric Environment 45, no. 40 (January 1, 2011): 7619–26. https://doi.org/10.1016/j.atmosenv.2010.10.009.
    Full Text
  - Stadler, Walter M., George Phillips, Daniel J. George, Susan Halabi, and Eric Small. “Bevacizumab and everolimus in renal cancer: a rational way forward..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 33 (November 2010): e692–93. https://doi.org/10.1200/jco.2010.30.7934.
    Full Text
  - Garber, Judy E., Susan Halabi, Sara M. Tolaney, Ellen Kaplan, Laura Archer, James N. Atkins, Stephen Edge, et al. “Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer..” Journal of the National Cancer Institute 102, no. 13 (July 2010): 942–49. https://doi.org/10.1093/jnci/djq211.
    Full Text
  - Kelly, W. K., S. Halabi, M. A. Carducci, D. J. George, J. F. Mahoney, W. M. Stadler, M. J. Morris, P. W. Kantoff, J. P. Monk, and E. J. Small. “A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401..” Journal of Clinical Oncology 28, no. 18_suppl (June 20, 2010): LBA4511–LBA4511. https://doi.org/10.1200/jco.2010.28.18_suppl.lba4511.
    Full Text
  - Armstrong, Andrew J., George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, et al. “A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 16, no. 11 (June 2010): 3057–66. https://doi.org/10.1158/1078-0432.CCR-10-0124.
    Full Text
  - Kelly, W. K., S. Halabi, M. A. Carducci, D. J. George, J. F. Mahoney, W. M. Stadler, M. J. Morris, P. W. Kantoff, J. P. Monk, and E. J. Small. “A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 18_suppl (June 2010).
  - Armstrong, A. J., D. J. George, and S. Halabi. “Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC).” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Armstrong, A. J., G. Kemeny, J. D. Turnbull, C. Chao, C. Winters, Y. A. Fesko, D. A. Bradley, S. Halabi, D. J. George, and M. Garcia-Blanco. “Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study..” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS249–TPS249. https://doi.org/10.1200/jco.2010.28.15_suppl.tps249.
    Full Text
  - Halabi, S., B. I. Rini, W. M. Stadler, and E. J. Small. “Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Gulley, James L., Philip M. Arlen, Ravi A. Madan, Kwong-Yok Tsang, Mary P. Pazdur, Lisa Skarupa, Jacquin L. Jones, et al. “Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer..” Cancer Immunol Immunother 59, no. 5 (May 2010): 663–74. https://doi.org/10.1007/s00262-009-0782-8.
    Full Text Link to Item
  - Rini, Brian I., Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, Laura Archer, James N. Atkins, et al. “Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206..” J Clin Oncol 28, no. 13 (May 1, 2010): 2137–43. https://doi.org/10.1200/JCO.2009.26.5561.
    Full Text Link to Item
  - Halabi, Susan, and Kouros Owzar. “The importance of identifying and validating prognostic factors in oncology..” Seminars in Oncology 37, no. 2 (April 2010): e9-18. https://doi.org/10.1053/j.seminoncol.2010.04.001.
    Full Text
  - Sartor, Oliver, David G. McLeod, Susan Halabi, Paul F. Schellhammer, Peter T. Scardino, Anthony V. D’Amico, Charles Bennett, John T. Wei, and John T. COMPARE Registry Steering Committee. “The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer..” Urology 75, no. 3 (March 2010): 623–29. https://doi.org/10.1016/j.urology.2009.04.059.
    Full Text
  - Armstrong, Andrew J., Ian F. Tannock, Ronald de Wit, Daniel J. George, Mario Eisenberger, and Susan Halabi. “The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival..” Eur J Cancer 46, no. 3 (February 2010): 517–25. https://doi.org/10.1016/j.ejca.2009.11.007.
    Full Text Link to Item
  - Regan, M. M., E. K. O’Donnell, W. K. Kelly, S. Halabi, W. Berry, S. Urakami, N. Kikuno, and W. K. Oh. “Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 21, no. 2 (February 2010): 312–18. https://doi.org/10.1093/annonc/mdp308.
    Full Text
  - Hagan, N., N. Robins, H. Hsu-Kim, S. Halabi, M. Morris, G. Woodall, T. Zhang, A. Bacon, D. D. B. Richter, and J. Vandenberg. “Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia.” Atmospheric Environment, 2010.
  - Bajorin, Dean F., Susan Halabi, and Eric Small. “Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903)..” Clinical Genitourinary Cancer 7, no. 3 (October 2009): E66–70. https://doi.org/10.3816/cgc.2009.n.026.
    Full Text
  - Fitzpatrick, J. M., C. N. Sternberg, F. Saad, M. Extermann, O. Caffo, S. Halabi, G. Kramer, S. Oudard, and R. de Wit. “Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment.” European Urology, Supplements 8, no. 9 (September 1, 2009): 738–46. https://doi.org/10.1016/j.eursup.2009.06.001.
    Full Text
  - Rini, B. I., S. Halabi, J. E. Rosenberg, B. Escudier, A. Pluzanska, P. Koralewski, and S. Hotte. “Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Update (vol 3, pg 200, 2009).” Cuaj Canadian Urological Association Journal 3, no. 4 (August 2009): 289–289.
    Link to Item
  - Halabi, Susan, Nicholas J. Vogelzang, San-San Ou, Kouros Owzar, Laura Archer, and Eric J. Small. “Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 17 (June 2009): 2766–71. https://doi.org/10.1200/JCO.2008.18.9159.
    Full Text
  - Philips, G. K., S. Halabi, B. L. Sanford, D. Bajorin, E. J. Small, and E. J. Cancer and Leukemia Group B. “A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 20, no. 6 (June 2009): 1074–79. https://doi.org/10.1093/annonc/mdn749.
    Full Text
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 18_suppl (June 2009).
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. J. George, R. DeWit, and M. Eisenberger. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009).
  - Halabi, S., O. Sartor, D. Petrylak, C. N. Sternberg, J. A. Witjes, M. Noursalehi, T. J. McKearn, and M. J. George. “Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009).
  - Luu, T., O. Sartor, N. Dandade, S. Halabi, and C. Bennett. “Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009).
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009).
  - Sartor, A. O., D. Petrylak, C. Sternberg, F. Witjes, S. Halabi, W. Berry, M. Petrone, T. McKearn, M. Noursalehi, and M. George. “Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009).
  - Bennett, Charles L., Oliver Sartor, Susan Halabi, and COMPARE Registry Committee. “PATIENT SATISFACTION WITH OBSERVATION OR HORMONAL THERAPY AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) AFTER BIOCHEMICAL FAILURE IN MEN WITH PROSTATE CANCER: RESULTS FROM THE COMPARE REGISTRY.” Journal of Urology 181, no. 4S (April 2009): 90–90. https://doi.org/10.1016/s0022-5347(09)60255-x.
    Full Text
  - Cole, Bernard F., Richard F. Logan, Susan Halabi, Robert Benamouzig, Robert S. Sandler, Matthew J. Grainge, Stanislas Chaussade, and John A. Baron. “Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials..” J Natl Cancer Inst 101, no. 4 (February 18, 2009): 256–66. https://doi.org/10.1093/jnci/djn485.
    Full Text Link to Item
  - Armstrong, A. J., S. Halabi, R. de Wit, I. F. Tannock, and M. Eisenberger. “The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer..” Prostate Cancer and Prostatic Diseases 12, no. 1 (January 2009): 88–93. https://doi.org/10.1038/pcan.2008.36.
    Full Text
  - Kelly, William Kevin, Susan Halabi, Aymen Elfiky, San-San Ou, Jeff Bogart, Michael Zelefsky, Eric Small, and Eric Cancer Leukemia Group B. “Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811..” Cancer 113, no. 11 (December 2008): 3137–45. https://doi.org/10.1002/cncr.23910.
    Full Text
  - Kim, Sangmi, Christopher Martin, Joseph Galanko, John T. Woosley, Jane C. Schroeder, Temitope O. Keku, Jessie A. Satia, Susan Halabi, and Robert S. Sandler. “Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans..” American Journal of Epidemiology 168, no. 11 (December 2008): 1292–1300. https://doi.org/10.1093/aje/kwn255.
    Full Text
  - Hurwitz, Mark D., Susan Halabi, San-San Ou, Lamar S. McGinnis, Michael R. Keuttel, Steven J. Dibiase, and Eric J. Small. “Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809..” International Journal of Radiation Oncology, Biology, Physics 72, no. 3 (November 2008): 814–19. https://doi.org/10.1016/j.ijrobp.2008.01.010.
    Full Text
  - Potthoff, Richard F., Susan Halabi, Joellen M. Schildkraut, and Beth Newman. “Flexible Frames and Control Sampling in Case-Control Studies: Weighters (Survey Statisticians) Versus Anti-Weighters (Epidemiologists)..” The American Statistician 62, no. 4 (November 2008): 307–13. https://doi.org/10.1198/000313008X364525.
    Full Text
  - Rini, Brian I., Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, San-San Ou, Laura Archer, et al. “Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 33 (November 2008): 5422–28. https://doi.org/10.1200/JCO.2008.16.9847.
    Full Text
  - Halabi, S., N. J. Vogelzang, A. B. Kornblith, S. S. Ou, P. W. Kantoff, N. A. Dawson, and E. J. Small. “In reply.” Journal of Clinical Oncology 26, no. 25 (September 18, 2008): 4216–17. https://doi.org/10.1200/JCO.2008.18.5496.
    Full Text
  - Scher, H. I., S. Halabi, I. F. Tannock, M. Morris, C. N. Sternberg, M. A. Carducci, M. A. Eisenberger, et al. “In reply.” Journal of Clinical Oncology 26, no. 21 (September 15, 2008): 3648–49. https://doi.org/10.1200/JCO.2008.17.2494.
    Full Text
  - Dawson, Nancy A., Susan Halabi, San-San Ou, David D. Biggs, Anne Kessinger, Nicholas Vogelzang, Gerald H. Clamon, et al. “A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004..” Clinical Genitourinary Cancer 6, no. 2 (September 2008): 110–16. https://doi.org/10.3816/cgc.2008.n.017.
    Full Text
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. Ronald, and M. A. Eisenberger. “The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 5074–5074. https://doi.org/10.1200/jco.2008.26.15_suppl.5074.
    Full Text
  - Shapiro, C. L., S. Halabi, G. Gibson, D. J. Weckstein, J. Kirshner, W. M. Sikov, E. P. Winer, et al. “Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).
    Link to Item
  - D’Amico, Anthony V., Susan Halabi, Clare Tempany, David Titelbaum, George K. Philips, Marian Loffredo, Elizabeth McMahon, et al. “Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study..” International Journal of Radiation Oncology, Biology, Physics 71, no. 1 (May 2008): 9–15. https://doi.org/10.1016/j.ijrobp.2007.09.033.
    Full Text
  - D’Amico, Anthony V., Susan Halabi, Robin Vollmer, Marian Loffredo, Elizabeth McMahon, Ben Sanford, Laura Archer, et al. “p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)..” Urology 71, no. 5 (May 2008): 933–37. https://doi.org/10.1016/j.urology.2007.11.005.
    Full Text
  - Halabi, Susan, Nicholas J. Vogelzang, Alice B. Kornblith, San-San Ou, Philip W. Kantoff, Nancy A. Dawson, and Eric J. Small. “Pain predicts overall survival in men with metastatic castration-refractory prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 15 (May 2008): 2544–49. https://doi.org/10.1200/jco.2007.15.0367.
    Full Text
  - Halabi, Susan. “Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer..” Urologic Oncology 26, no. 3 (May 2008): 300–307. https://doi.org/10.1016/j.urolonc.2006.11.007.
    Full Text
  - Moorman, Patricia G., Brian Calingaert, Rachel T. Palmieri, Edwin S. Iversen, Rex C. Bentley, Susan Halabi, Andrew Berchuck, and Joellen M. Schildkraut. “Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women..” Am J Epidemiol 167, no. 9 (May 1, 2008): 1059–69. https://doi.org/10.1093/aje/kwn006.
    Full Text Link to Item
  - Rosenberg, J. E., S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. J. Hohl, F. Millard, D. F. Bajorin, E. J. Small, and E. J. Cancer and Leukemia Group B. “Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207..” Ann Oncol 19, no. 5 (May 2008): 946–50. https://doi.org/10.1093/annonc/mdm600.
    Full Text Link to Item
  - Singh, B., S. Halabi, and M. J. Schell. “Sample size selection in clinical trials when population means are subject to a partial order: One-sided ordered alternatives.” Journal of Applied Statistics 35, no. 5 (May 1, 2008): 583–600. https://doi.org/10.1080/02664760801924780.
    Full Text
  - Scher, Howard I., Susan Halabi, Ian Tannock, Michael Morris, Cora N. Sternberg, Michael A. Carducci, Mario A. Eisenberger, et al. “Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group..” J Clin Oncol 26, no. 7 (March 1, 2008): 1148–59. https://doi.org/10.1200/JCO.2007.12.4487.
    Full Text Link to Item
  - Schildkraut, Joellen M., Patricia G. Moorman, Amy E. Bland, Susan Halabi, Brian Calingaert, Regina Whitaker, Paula S. Lee, et al. “Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup..” Cancer Epidemiol Biomarkers Prev 17, no. 3 (March 2008): 585–93. https://doi.org/10.1158/1055-9965.EPI-07-0596.
    Full Text Link to Item
  - Garmey, Edward G., Oliver Sartor, Susan Halabi, and Nicholas J. Vogelzang. “Second-line chemotherapy for advanced hormone-refractory prostate cancer..” Clinical Advances in Hematology & Oncology : H&O 6, no. 2 (February 2008): 118–32.
  - Kim, Sangmi, Temitope O. Keku, Christopher Martin, Joseph Galanko, John T. Woosley, Jane C. Schroeder, Jessie A. Satia, Susan Halabi, and Robert S. Sandler. “Circulating levels of inflammatory cytokines and risk of colorectal adenomas..” Cancer Res 68, no. 1 (January 1, 2008): 323–28. https://doi.org/10.1158/0008-5472.CAN-07-2924.
    Full Text Link to Item
  - Philips, George K., Susan Halabi, Ben L. Sanford, Dean Bajorin, Eric J. Small, and Eric J. Cancer and Leukaemia Group B. “A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102..” Bju Int 101, no. 1 (January 2008): 20–25. https://doi.org/10.1111/j.1464-410X.2007.07226.x.
    Full Text Link to Item
  - Potthoff, Richard F., Susan Halabi, Joellen M. Schildkraut, and Beth Newman. “Flexible Frames and Control Sampling in Case-Control Studies.” The American Statistician 62, no. 4 (2008): 307–13.
  - Halabi, Susan, San-San Ou, Nicholas J. Vogelzang, and Eric J. Small. “Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer..” Cancer 110, no. 7 (October 2007): 1478–84. https://doi.org/10.1002/cncr.22932.
    Full Text
  - Kyle, R. A., G. C. Yee, M. R. Somerfield, P. J. Flynn, S. Halabi, S. Jagannath, R. Z. Orlowski, D. G. Roodman, P. Twilde, and K. Anderson. “ASCO 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma: Guideline summary.” Journal of Oncology Practice 3, no. 4 (July 1, 2007). https://doi.org/10.1200/JOP.0748502.
    Full Text
  - Kyle, Robert A., Gary C. Yee, Mark R. Somerfield, Patrick J. Flynn, Susan Halabi, Sundar Jagannath, Robert Z. Orlowski, et al. “American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 17 (June 2007): 2464–72. https://doi.org/10.1200/jco.2007.12.1269.
    Full Text
  - Ryan, Charles J., Susan Halabi, San-San Ou, Nicholas J. Vogelzang, Philip Kantoff, and Eric J. Small. “Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 13, no. 7 (April 2007): 2030–37. https://doi.org/10.1158/1078-0432.ccr-06-2344.
    Full Text
  - Schildkraut, Joellen M., Susan K. Murphy, Rachel T. Palmieri, Edwin Iversen, Patricia G. Moorman, Zhiqing Huang, Susan Halabi, et al. “Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer..” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 16, no. 3 (March 2007): 473–80. https://doi.org/10.1158/1055-9965.epi-06-0868.
    Full Text
  - Halabi, Susan, Nicholas J. Vogelzang, San-San Ou, and Eric J. Small. “The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials..” J Urol 177, no. 2 (February 2007): 531–34. https://doi.org/10.1016/j.juro.2006.09.050.
    Full Text Link to Item
  - Stadler, Walter M., Susan Halabi, Brian Rini, Marc S. Ernstoff, Enrique Davila, Joel Picus, Robert Barrier, Eric J. Small, and Eric J. Cancer and Leukemia Group B. “A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008..” Cancer 107, no. 6 (September 15, 2006): 1273–79. https://doi.org/10.1002/cncr.22117.
    Full Text Link to Item
  - Halabi, Susan, Nicholas J. Vogelzang, San-San Ou, Wm Kevin Kelly, and Eric J. Small. “Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies..” The Journal of Urology 176, no. 1 (July 2006): 81–86. https://doi.org/10.1016/s0022-5347(06)00566-0.
    Full Text
  - Rini, Brian I., Susan Halabi, Robert Barrier, Kim A. Margolin, David Avigan, Theodore Logan, Walter M. Stadler, et al. “Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study..” Biol Blood Marrow Transplant 12, no. 7 (July 2006): 778–85. https://doi.org/10.1016/j.bbmt.2006.03.011.
    Full Text Link to Item
  - Halabi, S., S. Ou, N. J. Vogelzang, and E. J. Small. “An elevated body mass (BMI) index predicts for better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC)..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).
    Link to Item
  - Philips, G., B. Sanford, S. Halabi, D. Bajorin, and E. J. Small. “Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).
    Link to Item
  - Picus, J., S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang. “Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).
    Link to Item
  - Rosenberg, J. E., S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. Hohl, S. L. Seagren, D. F. Bajorin, and E. J. Small. “CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC)..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).
    Link to Item
  - Sartor, O., C. L. Bennett, S. Halabi, M. Kattan, and P. Scardino. “Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).
    Link to Item
  - Small, E. J., S. Halabi, P. Kantoff, A. D’Amico, W. Stadler, W. K. Kelley, J. Mohler, D. Bajorin, and N. J. Vogelzang. “Activities and accomplishments of the Cancer and Leukemia Group B Genitourinary Committee.” Clinical Cancer Research 12, no. 11 II (June 1, 2006). https://doi.org/10.1158/1078-0432.CCR-06-9005.
    Full Text
  - Small, Eric J., Susan Halabi, Phillip Kantoff, Anthony D’Amico, Walter Stadler, W Kevin Kelley, James Mohler, Dean Bajorin, and Nicholas J. Vogelzang. “Activities and accomplishments of the cancer and leukemia group B genitourinary committee..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 12, no. 11 Pt 2 (June 2006): 3596s-3600s. https://doi.org/10.1158/1078-0432.ccr-06-9005.
    Full Text
  - Humphrey, Peter A., Susan Halabi, Joel Picus, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. “Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480..” Clin Genitourin Cancer 4, no. 4 (March 2006): 269–74. https://doi.org/10.3816/CGC.2006.n.006.
    Full Text Link to Item
  - Schildkraut, Joellen M., Patricia G. Moorman, Susan Halabi, Brian Calingaert, Jeffrey R. Marks, and Andrew Berchuck. “Analgesic drug use and risk of ovarian cancer..” Epidemiology (Cambridge, Mass.) 17, no. 1 (January 2006): 104–7. https://doi.org/10.1097/01.ede.0000190538.55645.f8.
    Full Text
  - Ross, Robert W., Susan Halabi, San-San Ou, Barur R. Rajeshkumar, Bruce A. Woda, Nicholas J. Vogelzang, Eric J. Small, Mary-Ellen Taplin, Philip W. Kantoff, and Philip W. Cancer and Leukemia Group B. “Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study..” Clin Cancer Res 11, no. 22 (November 15, 2005): 8109–13. https://doi.org/10.1158/1078-0432.CCR-05-1250.
    Full Text Link to Item
  - Hoyo, Cathrine, Andrew Berchuck, Susan Halabi, Rex C. Bentley, Patricia Moorman, Brian Calingaert, and Joellen M. Schildkraut. “Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women..” Cancer Causes Control 16, no. 8 (October 2005): 955–63. https://doi.org/10.1007/s10552-005-3205-y.
    Full Text Link to Item
  - Taplin, Mary-Ellen, Daniel J. George, Susan Halabi, Ben Sanford, Philip G. Febbo, Kristen T. Hennessy, Christos G. Mihos, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. “Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study..” Urology 66, no. 2 (August 2005): 386–91. https://doi.org/10.1016/j.urology.2005.03.040.
    Full Text Link to Item
  - Moorman, Patricia G., Joellen M. Schildkraut, Brian Calingaert, Susan Halabi, and Andrew Berchuck. “Menopausal hormones and risk of ovarian cancer..” American Journal of Obstetrics and Gynecology 193, no. 1 (July 2005): 76–82. https://doi.org/10.1016/j.ajog.2004.11.013.
    Full Text
  - Moorman, P. G., A. Berchuck, B. Calingaert, S. Halabi, and A. M. Schildkraut. “Antidepressant medication use for and risk of ovarian cancer (vol 105, pg 725, 2005).” Obstetrics and Gynecology 105, no. 6 (June 2005): 1495–1495.
    Link to Item
  - Moorman, P. G., A. Berchuck, B. Calingaert, S. Halabi, and M. Schildkraut. “Erratum: Antidepressant medication use for and risk of ovarian cancer (Obstetrics and Gynecology (2005) 105 (725-730)).” Obstetrics and Gynecology 105, no. 6 (June 1, 2005). https://doi.org/10.1097/01.AOG.0000151956.00804.78.
    Full Text
  - Spillman, Monique A., Joellen M. Schildkraut, Susan Halabi, Patricia Moorman, Brian Calingaert, Rex C. Bentley, Jeffrey R. Marks, Susan Murphy, and Andrew Berchuck. “Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk..” Gynecol Oncol 97, no. 2 (May 2005): 543–49. https://doi.org/10.1016/j.ygyno.2005.01.025.
    Full Text Link to Item
  - Halabi, Susan, Eric J. Small, and Nicholas J. Vogelzang. “Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 10 (April 2005): 2434–35. https://doi.org/10.1200/jco.2005.05.890.
    Full Text
  - Moorman, Patricia G., Andrew Berchuck, Brian Calingaert, Susan Halabi, and Joellen M. Schildkraut. “Antidepressant medication use [corrected] and risk of ovarian cancer..” Obstetrics and Gynecology 105, no. 4 (April 2005): 725–30. https://doi.org/10.1097/01.aog.0000157113.98061.eb.
    Full Text
  - George, Daniel J., Susan Halabi, Timothy F. Shepard, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. “The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 11, no. 5 (March 2005): 1815–20. https://doi.org/10.1158/1078-0432.ccr-04-1560.
    Full Text
  - Berchuck, Andrew, Joellen M. Schildkraut, Robert M. Wenham, Brian Calingaert, Shazia Ali, Amy Henriott, Susan Halabi, et al. “Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers..” Cancer Epidemiol Biomarkers Prev 13, no. 12 (December 2004): 2141–47.
    Link to Item
  - Amin, Asim, Susan Halabi, Edward P. Gelmann, Walter Stadler, Nicholas Vogelzang, and Eric Small. “9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901..” Urologic Oncology 22, no. 5 (September 2004): 398–403. https://doi.org/10.1016/j.urolonc.2004.05.002.
    Full Text
  - Halabi, Susan, Eric J. Small, Nicholas J. Vogelzang, Robert C. Barrier, Stephen L. George, and Timothy D. Gilligan. “Impact of race on survival in men with metastatic hormone-refractory prostate cancer..” Urology 64, no. 2 (August 2004): 212–17. https://doi.org/10.1016/j.urology.2004.04.014.
    Full Text
  - Burns, C Patrick, Susan Halabi, Gerald Clamon, Ellen Kaplan, Raymond J. Hohl, James N. Atkins, Michael A. Schwartz, Brett A. Wagner, and Electra Paskett. “Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia..” Cancer 101, no. 2 (July 2004): 370–78. https://doi.org/10.1002/cncr.20362.
    Full Text
  - D’Amico, A. V., S. Halabi, N. J. Vogelzang, and E. J. Small. “A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).
  - Halabi, S., E. J. Small, T. Gilligian, R. Barrier, S. George, and N. J. Vogelzang. “The effect of race on progression-free survival in patients with metastatic hormone-refractory prostate cancer (HRPC): a pooled analysis of CALGB studies..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).
  - Humphrey, P., S. Halabi, J. Picus, N. Vogelzang, E. Small, and P. Kantoff. “Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).
  - Philips, G., S. Halabi, B. Sanford, D. Bajorin, and E. Small. “Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).
  - Picus, J., S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang. “Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).
  - Ryan, C. J., S. Halabi, E. Kaplan, N. Vogelzang, P. Kantoff, and E. J. Small. “Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).
  - Stadler, W. M., S. Halabi, M. S. Ernstoff, R. Barrier, E. Davila, J. Picus, and E. J. Small. “A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).
  - Taplin, M. E., D. J. George, S. Halabi, W. R. Sellers, B. Sanford, K. T. Hennessy, C. G. Mihos, E. J. Small, and P. W. Kantoff. “Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).
  - Halabi, Susan, and Bahadur Singh. “Sample size determination for comparing several survival curves with unequal allocations..” Stat Med 23, no. 11 (June 15, 2004): 1793–1815. https://doi.org/10.1002/sim.1771.
    Full Text Link to Item
  - Rini, Brian I., Susan Halabi, John Taylor, Eric J. Small, Richard L. Schilsky, and Richard L. Cancer and Leukemia Group B. “Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma..” Clin Cancer Res 10, no. 8 (April 15, 2004): 2584–86.
    Link to Item
  - Small, Eric J., Susan Halabi, Nancy A. Dawson, Walter M. Stadler, Brian I. Rini, Joel Picus, Preston Gable, Frank M. Torti, Ellen Kaplan, and Nicholas J. Vogelzang. “Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)..” J Clin Oncol 22, no. 6 (March 15, 2004): 1025–33. https://doi.org/10.1200/JCO.2004.06.037.
    Full Text Link to Item
  - Scher, Howard I., Mario Eisenberger, Anthony V. D’Amico, Susan Halabi, Eric J. Small, Michael Morris, Michael W. Kattan, et al. “Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 3 (February 2004): 537–56. https://doi.org/10.1200/jco.2004.07.099.
    Full Text
  - Burns, C. P., S. Halabi, G. Clamon, E. Kaplan, R. J. Hohl, J. N. Atkins, M. A. Schwartz, B. A. Wagner, and E. Paskett. “Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia: A cancer and leukemia group B study.” Cancer 101, no. 2 (2004): 370–78. https://doi.org/10.1002/cncr.20362.
    Full Text
  - Oh, William K., Susan Halabi, W Kevin Kelly, Cary Werner, Paul A. Godley, Nicholas J. Vogelzang, Eric J. Small, and Eric J. Cancer and Leukemia Group B 99813. “A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813..” Cancer 98, no. 12 (December 2003): 2592–98. https://doi.org/10.1002/cncr.11829.
    Full Text
  - Sandler, R. S., S. Halabi, and J. A. Baron. “Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer.” Evidence Based Medicine 8, no. 6 (November 1, 2003). https://doi.org/10.1136/ebm.8.6.179.
    Full Text
  - Taplin, Mary-Ellen, Barur Rajeshkumar, Susan Halabi, Cary P. Werner, Bruce A. Woda, Joel Picus, Walter Stadler, et al. “Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663..” J Clin Oncol 21, no. 14 (July 15, 2003): 2673–78. https://doi.org/10.1200/JCO.2003.11.102.
    Full Text Link to Item
  - Halabi, Susan, Chuan-Chuan Wun, and Barry R. Davis. “Analysis of survival data with missing measurements of a time-dependent binary covariate..” Journal of Biopharmaceutical Statistics 13, no. 2 (May 2003): 253–70. https://doi.org/10.1081/bip-120019270.
    Full Text
  - Small, E. J., S. Halabi, G. Dalbagni, R. Pruthi, G. Phillips, M. Edelman, and D. Bajorin. “Overview of bladder cancer trials in the cancer and leukemia group B.” Cancer 97, no. 8 SUPPL. (April 15, 2003): 2090–98.
  - Halabi, Susan, Eric J. Small, Philip W. Kantoff, Michael W. Kattan, Ellen B. Kaplan, Nancy A. Dawson, Ellis G. Levine, Brent A. Blumenstein, and Nicholas J. Vogelzang. “Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 21, no. 7 (April 2003): 1232–37. https://doi.org/10.1200/jco.2003.06.100.
    Full Text
  - Small, Eric J., Susan Halabi, Guido Dalbagni, Raj Pruthi, George Phillips, Martin Edelman, Dean Bajorin, and Dean Cancer and Leukemia Group B. “Overview of bladder cancer trials in the Cancer and Leukemia Group B..” Cancer 97, no. 8 Suppl (April 2003): 2090–98. https://doi.org/10.1002/cncr.11299.
    Full Text
  - Sandler, Robert S., Susan Halabi, John A. Baron, Susan Budinger, Electra Paskett, Roger Keresztes, Nicholas Petrelli, et al. “A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer..” N Engl J Med 348, no. 10 (March 6, 2003): 883–90. https://doi.org/10.1056/NEJMoa021633.
    Full Text Link to Item
  - Lancaster, Johnathan M., Robert M. Wenham, Susan Halabi, Brian Calingaert, Jeffrey R. Marks, Patricia G. Moorman, Rex C. Bentley, Andrew Berchuck, and Joellen M. Schildkraut. “No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina..” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 12, no. 3 (March 2003): 226–27.
  - Halabi, Susan, Eric J. Small, Daniel F. Hayes, Nicholas J. Vogelzang, and Philip W. Kantoff. “Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 21, no. 3 (February 2003): 490–95. https://doi.org/10.1200/jco.2003.04.104.
    Full Text
  - HALBI, S. “Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.” J Clin Oncol 21 (2003): 1232–37. https://doi.org/10.1200/JCO.2003.06.100.
    Full Text
  - Sandler, R. S., S. Halabi, J. A. Baron, S. Budinger, E. Paskett, R. Keresztes, N. Petrelli, et al. “A randomized trial of aspirin to prevent colorectal adenomas in patients with previous.” European Journal of Gastroenterology and Hepatology 15, no. 5 (January 1, 2003): 579–80. https://doi.org/10.1097/00042737-200305000-00032.
    Full Text
  - Moorman, Patricia G., Joellen M. Schildkraut, Brian Calingaert, Susan Halabi, Marilyn F. Vine, and Andrew Berchuck. “Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States)..” Cancer Causes Control 13, no. 9 (November 2002): 807–11.
    Link to Item
  - Small, Eric J., Susan Halabi, Mark J. Ratain, Gary Rosner, Walter Stadler, David Palchak, Ernest Marshall, et al. “Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 20, no. 16 (August 2002): 3369–75. https://doi.org/10.1200/jco.2002.10.022.
    Full Text
  - McBride, Colleen M., Lori A. Bastian, Susan Halabi, Laura Fish, Isaac M. Lipkus, Hayden B. Bosworth, Barbara K. Rimer, and Ilene C. Siegler. “A tailored intervention to aid decision-making about hormone replacement therapy..” Am J Public Health 92, no. 7 (July 2002): 1112–14.
    Link to Item
  - Rimer, Barbara K., Susan Halabi, Celette Sugg Skinner, Isaac M. Lipkus, Tara S. Strigo, Ellen B. Kaplan, and Gregory P. Samsa. “Effects of a mammography decision-making intervention at 12 and 24 months..” Am J Prev Med 22, no. 4 (May 2002): 247–57.
    Link to Item
  - Levine, Ellis G., Susan Halabi, John D. Roberts, Ellen B. Kaplan, Randall Rago, James N. Atkins, and Nicholas J. Vogelzang. “Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study..” Cancer 94, no. 3 (February 2002): 665–72. https://doi.org/10.1002/cncr.10217.
    Full Text
  - Halabi, S., M. R. Conaway, E. J. Small, N. J. Vogelzang, and N. A. Dawson. “Serum prostate specific antigen as a predictor of survival in prostate cancer patients treated with second-line hormonal therapy (CALGB 9181).” Prostate Journal 3, no. 1 (September 27, 2001): 18–25. https://doi.org/10.1046/j.1525-1411.2001.31003.x.
    Full Text
  - Bastian, L. A., I. M. Lipkus, M. N. Kuchibhatla, H. H. Weng, S. Halabi, P. D. Ryan, C. S. Skinner, and B. K. Rimer. “Women's interest in chemoprevention for breast cancer..” Archives of Internal Medicine 161, no. 13 (July 2001): 1639–44. https://doi.org/10.1001/archinte.161.13.1639.
    Full Text
  - George, D. J., S. Halabi, T. F. Shepard, N. J. Vogelzang, D. F. Hayes, E. J. Small, P. W. Kantoff, and P. W. Cancer and Leukemia Group B 9480. “Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 7, no. 7 (July 2001): 1932–36.
  - Schildkraut, J. M., G. S. Cooper, S. Halabi, B. Calingaert, P. Hartge, and A. S. Whittemore. “Age at natural menopause and the risk of epithelial ovarian cancer..” Obstetrics and Gynecology 98, no. 1 (July 2001): 85–90. https://doi.org/10.1016/s0029-7844(01)01388-6.
    Full Text
  - Halabi, S., J. M. Schildkraut, G. S. Cooper, B. Calingaert, P. Hartge, and A. S. Whittemore. “Age at natural menopause and the risk of developing invasive epithelial ovarian cancer..” American Journal of Epidemiology 153, no. 11 (June 1, 2001): S111–S111.
    Link to Item
  - Kantoff, P. W., S. Halabi, D. A. Farmer, D. F. Hayes, N. A. Vogelzang, and E. J. Small. “Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 19, no. 12 (June 2001): 3025–28. https://doi.org/10.1200/jco.2001.19.12.3025.
    Full Text
  - Moorman, P. G., B. Calingaert, M. Vine, S. Halabi, A. Berchuck, and J. M. Schildkraut. “Comparison of two methods for calculating lifetime ovulatory cycles..” American Journal of Epidemiology 153, no. 11 (June 1, 2001): S138–S138.
    Link to Item
  - Rimer, B. K., S. Halabi, C. Sugg Skinner, E. B. Kaplan, Y. Crawford, G. P. Samsa, T. S. Strigo, and I. M. Lipkus. “The short-term impact of tailored mammography decision-making interventions..” Patient Education and Counseling 43, no. 3 (June 2001): 269–85. https://doi.org/10.1016/s0738-3991(00)00172-5.
    Full Text
  - Savarese, D. M., S. Halabi, V. Hars, W. L. Akerley, M. E. Taplin, P. A. Godley, A. Hussain, E. J. Small, and N. J. Vogelzang. “Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 19, no. 9 (May 2001): 2509–16. https://doi.org/10.1200/jco.2001.19.9.2509.
    Full Text
  - Bok, R. A., S. Halabi, D. T. Fei, C. R. Rodriquez, D. F. Hayes, N. J. Vogelzang, P. Kantoff, M. A. Shuman, and E. J. Small. “Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study..” Cancer Research 61, no. 6 (March 2001): 2533–36.
  - Sandler, R. S., S. Halabi, E. B. Kaplan, J. A. Baron, E. Paskett, and N. J. Petrelli. “Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial..” Cancer 91, no. 5 (March 1, 2001): 1040–45.
    Link to Item
  - Suba, E. J., C. H. Nguyen, B. D. Nguyen, S. S. Raab, and S. S. Viet/American Cervical Cancer Prevention Project. “De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam..” Cancer 91, no. 5 (March 2001): 928–39. https://doi.org/10.1002/1097-0142(20010301)91:5<928::aid-cncr1082>3.0.co;2-s.
    Full Text
  - Halabi, S., C. S. Skinner, G. P. Samsa, T. S. Strigo, Y. S. Crawford, and B. K. Rimer. “Factors associated with repeat mammography screening..” J Fam Pract 49, no. 12 (December 2000): 1104–12.
    Link to Item
  - Lipkus, I. M., M. Kuchibhatla, C. M. McBride, H. B. Bosworth, K. I. Pollak, I. C. Siegler, and B. K. Rimer. “Relationships among breast cancer perceived absolute risk, comparative risk, and worries..” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 9, no. 9 (September 2000): 973–75.
  - Lipkus, I. M., S. Halabi, T. S. Strigo, and B. K. Rimer. “The impact of abnormal mammograms on psychosocial outcomes and subsequent screening..” Psychooncology 9, no. 5 (September 2000): 402–10.
    Link to Item
  - Alpers, L., K. Chrouser, S. Halabi, T. Moeti, A. Reingold, N. Binkin, and T. Kenyon. “Validation of the surveillance system for tuberculosis in Botswana..” The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union Against Tuberculosis and Lung Disease 4, no. 8 (August 2000): 737–43.
  - McBride, C. M., S. Halabi, G. Bepler, P. Lyna, L. McIntyre, I. Lipkus, J. Albright, and K. O’Briant. “Maximizing the motivational impact of feedback of lung cancer susceptibility on smokers' desire to quit..” Journal of Health Communication 5, no. 3 (July 2000): 229–41. https://doi.org/10.1080/10810730050131406.
    Full Text
  - Dawson, N. A., M. Conaway, S. Halabi, E. P. Winer, E. J. Small, D. Lake, and N. J. Vogelzang. “A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181..” Cancer 88, no. 4 (February 2000): 825–34. https://doi.org/10.1002/(sici)1097-0142(20000215)88:4<825::aid-cncr13>3.0.co;2-n.
    Full Text
  - Demark-Wahnefried, W., S. Halabi, V. Hars, E. Winer, P. K. Marcom, K. Blackwell, L. Harris, and B. K. Rimer. “Increased weight & body fatness associated with chemotherapy for breast cancer ... & what can be done?.” Cancer Epidemiology Biomarkers & Prevention 9, no. 2 (February 1, 2000): 236–236.
    Link to Item
  - Lipkus, I. M., B. K. Rimer, S. Halabi, and T. S. Strigo. “Can tailored interventions increase mammography use among HMO women?.” Am J Prev Med 18, no. 1 (January 2000): 1–10.
    Link to Item
  - Schildkraut, J. M., S. Halabi, E. Bastos, P. A. Marchbanks, J. A. McDonald, and A. Berchuck. “Prognostic factors in early-onset epithelial ovarian cancer: a population-based study..” Obstetrics and Gynecology 95, no. 1 (January 2000): 119–27. https://doi.org/10.1016/s0029-7844(99)00535-9.
    Full Text
  - Burns, C. P., S. Halabi, G. H. Clamon, V. Hars, B. A. Wagner, R. J. Hohl, E. Lester, J. J. Kirshner, V. Vinciguerra, and E. Paskett. “Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473..” Clin Cancer Res 5, no. 12 (December 1999): 3942–47.
    Link to Item
  - Savarese, D., M. E. Taplin, S. Halabi, V. Hars, W. Kreis, and N. Vogelzang. “A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780.” Seminars in Oncology 26, no. 5 SUPPL. 17 (December 1, 1999): 39–44.
  - Bastian, L. A., C. M. McBride, S. Halabi, L. J. Fish, C. S. Skinner, E. B. Kaplan, H. B. Bosworth, B. K. Rimer, and I. C. Siegler. “Attitudes and Knowledge Associated with being Undecided about Hormone Replacement Therapy: Results from a Community Sample.” Women’S Health Issues 9, no. 6 (November 1999): 330–37. https://doi.org/10.1016/s1049-3867(99)90001-4.
    Full Text
  - Bubley, G. J., M. Carducci, W. Dahut, N. Dawson, D. Daliani, M. Eisenberger, W. D. Figg, et al. “Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group..” J Clin Oncol 17, no. 11 (November 1999): 3461–67. https://doi.org/10.1200/JCO.1999.17.11.3461.
    Full Text Link to Item
  - Savarese, D., M. E. Taplin, S. Halabi, V. Hars, W. Kreis, and N. Vogelzang. “A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780..” Seminars in Oncology 26, no. 5 Suppl 17 (October 1999): 39–44.
  - Savarese, D., M. E. Taplin, S. Halabi, V. Hars, W. Kreis, and N. Vogelzang. “A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780.” Seminars in Oncology 26, no. 5 (October 1, 1999): 39–44.
    Link to Item
  - Kantoff, P. W., S. Halabi, M. Conaway, J. Picus, J. Kirshner, V. Hars, D. Trump, E. P. Winer, and N. J. Vogelzang. “Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 17, no. 8 (August 1999): 2506–13. https://doi.org/10.1200/jco.1999.17.8.2506.
    Full Text
  - Rimer, B. K., S. Halabi, T. S. Strigo, Y. Crawford, and I. M. Lipkus. “Confusion about mammography: prevalence and consequences..” Journal of Women’S Health & Gender Based Medicine 8, no. 4 (May 1999): 509–20. https://doi.org/10.1089/jwh.1.1999.8.509.
    Full Text
  - Anreder, M. B., S. M. Freeman, A. Merogi, S. Halabi, and A. J. Marrogi. “p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases..” Archives of Pathology & Laboratory Medicine 123, no. 4 (April 1999): 310–16. https://doi.org/10.1043/0003-9985(1999)123<0310:pceaps>2.0.co;2.
    Full Text
  - E S Johnson S Halabi G Netto G Lucier W Bechtold R Henderson, Kenneth A. “Detection of low level benzene exposure in supermarket wrappers by urinary muconic acid..” Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals 4, no. 2 (January 1999): 106–17. https://doi.org/10.1080/135475099230912.
    Full Text
  - Demark-Wahnefried, W., S. Halabi, and D. F. Paulson. “Serum androgens: associations with prostate cancer risk and hair patterning..” Journal of Andrology 19, no. 5 (September 1998).
  - Demark-Wahnefried, W., S. Halabi, and D. F. Paulson. “Untitled.” Journal of Andrology 19, no. 5 (September 1, 1998): 631–631.
    Link to Item
  - Coughlin, S. S., S. Halabi, and C. Metayer. “Barriers to cardiac transplantation in idiopathic dilated cardiomyopathy: the Washington, DC, Dilated Cardiomyopathy Study..” Journal of the National Medical Association 90, no. 6 (June 1998): 342–48.
  - Demark-Wahnefried, W., S. Halabi, and D. F. Paulson. “Letter to the editor.” Journal of Andrology 19, no. 5 (January 1, 1998).
  - Schildkraut, J. M., E. Bastos, S. Halabi, and A. Berchuck. “Response.” Jnci Journal of the National Cancer Institute 89, no. 22 (November 19, 1997): 1727–1727. https://doi.org/10.1093/jnci/89.22.1727.
    Full Text
  - Wodnicki, P., S. Lockett, M. Rhadhakrishna Pillai, S. Halabi, A. McKalip, and B. Herman. “Automated image microscopy.” Chemical Analysis 137 (December 1, 1996): 31–54.
  - Coughlin, S. S., S. Halabi, and C. Metayer. “Barriers to cardiac transplantation in idiopathic dilated cardiomyopathy: The Washington, DC dilated cardiomyopathy study.” Circulation 94, no. 8 (October 15, 1996): 4043–4043.
    Link to Item
  - Becher, R., O. Kloke, J. Hayungs, G. Hartwich, H. Bartels, J. Szanto, E. Wolf, et al. “Epirubicin and ifosfamide in metastatic breast cancer.” Seminars in Oncology 23, no. 3 SUPPL. 7 (August 27, 1996): 28–33.
  - Crane, M. M., S. S. Strom, S. Halabi, E. L. Berman, J. J. Fueger, M. R. Spitz, and M. J. Keating. “Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia..” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 5, no. 8 (August 1996): 639–44.
  - Becher, R., O. Kloke, J. Hayungs, G. Hartwich, H. Bartels, J. Szanto, E. Wolf, et al. “Epirubicin and ifosfamide in metastatic breast cancer..” Seminars in Oncology 23, no. 3 Suppl 7 (June 1996): 28–33.
  - Pillai, M. R., S. Halabi, A. McKalip, P. G. Jayaprakash, T. N. Rajalekshmi, M. K. Nair, and B. Herman. “The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer..” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 5, no. 5 (May 1996): 329–35.
  - Munshi, A., O. L. Marrogi, S. Halabi, A. I. Merogi, S. M. Freeman, and A. I. Marrogi. “Oncogene profile in pre versus postmenopausal women with breast carcinoma: Evidence of different p53 mutation patterns.” Faseb Journal 10, no. 6 (April 30, 1996): 839–839.
    Link to Item
  - Ji, W., G. Z. Qu, P. Ye, X. Y. Zhang, S. Halabi, and M. Ehrlich. “Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay..” Cancer Research 55, no. 13 (July 1995): 2876–82.
  - Bondy, M. L., E. D. Lustbader, S. Halabi, E. Ross, and V. G. Vogel. “Validation of a breast cancer risk assessment model in women with a positive family history..” J Natl Cancer Inst 86, no. 8 (April 20, 1994): 620–25. https://doi.org/10.1093/jnci/86.8.620.
    Full Text Link to Item
  - Vernon, S. W., V. G. Vogel, S. Halabi, and M. L. Bondy. “Factors associated with perceived risk of breast cancer among women attending a screening program..” Breast Cancer Research and Treatment 28, no. 2 (November 1993): 137–44. https://doi.org/10.1007/bf00666426.
    Full Text
  - Schusterman, M. A., S. S. Kroll, G. P. Reece, M. J. Miller, N. Ainslie, S. Halabi, and C. M. Balch. “Incidence of autoimmune disease in patients after breast reconstruction with silicone gel implants versus autogenous tissue: a preliminary report..” Annals of Plastic Surgery 31, no. 1 (July 1993): 1–6.
  - Spitz, M. R., J. J. Fueger, S. Halabi, S. P. Schantz, D. Sample, and T. C. Hsu. “Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis..” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2, no. 4 (July 1993): 329–33.
  - Peters, G. N., V. G. Vogel, W. P. Evans, M. Bondy, S. Halabi, J. Lord, and E. A. Laville. “The Texas Breast Screening Project: Part I. Mammographic and clinical results..” Southern Medical Journal 86, no. 4 (April 1993): 385–90.
  - Vogel, V. G., M. Bondy, S. Halabi, J. Lord, and E. A. Laville. “The Texas Breast Screening Project: Part II. Demographics, risk profiles, and health practices of participants..” Southern Medical Journal 86, no. 4 (April 1993): 391–96.
  - Bondy, M. L., M. R. Spitz, S. Halabi, J. J. Fueger, S. P. Schantz, D. Sample, and T. C. Hsu. “Association between family history of cancer and mutagen sensitivity in upper aerodigestive tract cancer patients..” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2, no. 2 (March 1993): 103–6.
  - Halabi, S., V. G. Vogel, M. L. Bondy, and S. W. Vernon. “Recruiting older women for screening mammography..” Cancer Detection and Prevention 17, no. 3 (January 1993): 359–65.
  - Bondy, M. L., M. R. Spitz, S. Halabi, J. J. Fueger, and V. G. Vogel. “Low incidence of familial breast cancer among Hispanic women..” Cancer Causes & Control : Ccc 3, no. 4 (July 1992): 377–82. https://doi.org/10.1007/bf00146892.
    Full Text
  - Halabi, S., H. Zurayk, R. Awaida, M. Darwish, and B. Saab. “Reliability and validity of self and proxy reporting of morbidity data: a case study from Beirut, Lebanon..” International Journal of Epidemiology 21, no. 3 (June 1992): 607–12. https://doi.org/10.1093/ije/21.3.607.
    Full Text
  - Bondy, M. L., V. G. Vogel, S. Halabi, and E. D. Lustbader. “Identification of women at increased risk for breast cancer in a population-based screening program..” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 1, no. 2 (January 1992): 143–47.
  - Vernon, S. W., V. G. Vogel, S. Halabi, G. L. Jackson, R. O. Lundy, and G. N. Peters. “Breast cancer screening behaviors and attitudes in three racial/ethnic groups..” Cancer 69, no. 1 (January 1992): 165–74. https://doi.org/10.1002/1097-0142(19920101)69:1<165::aid-cncr2820690128>3.0.co;2-f.
    Full Text
  - Armenian, H. K., S. S. Halabi, and M. Khlat. “Epidemiology of primary health problems in Beirut..” Journal of Epidemiology and Community Health 43, no. 4 (December 1989): 315–18. https://doi.org/10.1136/jech.43.4.315.
    Full Text
  - Armenian, H. K., N. G. Lakkis, A. M. Sibai, and S. S. Halabi. “Hospital visitors as controls..” American Journal of Epidemiology 127, no. 2 (February 1988): 404–6. https://doi.org/10.1093/oxfordjournals.aje.a114813.
    Full Text
  - Zurayk, H., S. Halabi, and M. Deeb. “Measures of social class based on education for use in health studies in developing countries..” Journal of Epidemiology and Community Health 41, no. 2 (June 1987): 173–79. https://doi.org/10.1136/jech.41.2.173.
    Full Text
  - Khlat, M., S. Halabi, A. Khudr, and V. M. Der Kaloustian. “Perception of consanguineous marriages and their genetic effects among a sample of couples from Beirut..” American Journal of Medical Genetics 25, no. 2 (October 1986): 299–306. https://doi.org/10.1002/ajmg.1320250215.
    Full Text
  - Khlat, M., and S. Halabi. “Modernization and consanguineous marriage in Beirut..” J Biosoc Sci 18, no. 4 (October 1986): 489–95.
    Link to Item
- Conference Papers
  - Koontz, B. F., K. E. Hoffman, P. Healy, D. J. George, M. R. Harrison, T. Zhang, W. R. Lee, et al. “Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 102:S100–S100. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2018.06.256.
    Full Text
  - George, D. J., A. J. Pantuck, R. Figlin, B. Escudier, S. Halabi, M. Casey, X. Lin, L. Serfass, MJ Lechuga Frean, and A. Ravaud. “Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.” In Annals of Oncology, 29:312–312. OXFORD UNIV PRESS, 2018.
    Link to Item
  - Ryan, C. J., S. Dutta, W. Kelly, M. J. Morris, M. -. E. Taplin, and S. Halabi. “Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone plus /- bevacizumab (B).” In Annals of Oncology, 29:283–283. OXFORD UNIV PRESS, 2018.
    Link to Item
  - George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP)..” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.
    Link to Item
  - Armstrong, Andrew J., Santosh Gupta, Patrick Healy, Gabor Kemeny, Lauren Beth Leith, Michael Zalutsky, Charles Spritzer, et al. “Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223..” In Journal of Clinical Oncology, 36:160–160. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.160.
    Full Text
  - George, Daniel J., Colin Hessel, Susan Halabi, Ben L. Sanford, M Dror Michaelson, Olwen Mary Hahn, Meghara K. Walsh, et al. “Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial..” In Journal of Clinical Oncology, 36:582–582. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.582.
    Full Text
  - Koontz, Bridget F., Karen E. Hoffman, Patrick Healy, Daniel J. George, Michael Roger Harrison, Tian Zhang, W Robert Lee, et al. “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer..” In Journal of Clinical Oncology, 36:11–11. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.11.
    Full Text
  - Beltran, Himisha, Alexander W. Wyatt, Edmund C. Chedgy, Adam Donoghue, Matti Annala, Evan W. Warner, Kevin Beja, et al. “Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy..” In Clin Cancer Res, 23:6802–11, 2017. https://doi.org/10.1158/1078-0432.CCR-17-1034.
    Full Text Link to Item
  - Choueiri, T. K., C. Hessel, S. Halabi, B. Sanford, O. Hahn, M. D. Michaelson, M. Walsh, et al. “Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
    Link to Item
  - Armstrong, Andrew J., Susan Halabi, Patrick Healy, Joshi J. Alumkal, Carolyn Winters, Julie Kephart, Rhonda L. Bitting, et al. “Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer..” In European Journal of Cancer (Oxford, England : 1990), 81:228–36, 2017. https://doi.org/10.1016/j.ejca.2017.02.030.
    Full Text
  - Slovin, Susan F., Karen E. Knudsen, Susan Halabi, Emily Carbone, Celina Fernandez, Yu Chen, Karen A. Autio, et al. “Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy..” In Journal of Clinical Oncology, 35:5034–5034. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.5034.
    Full Text
  - Halabi, Susan, and Sandipan Dutta. “Two new residuals in survival analysis with full likelihood.” In Trials, Vol. 18. BIOMED CENTRAL LTD, 2017.
    Link to Item
  - Armstrong, Andrew J., Michael S. Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R. Harrison, et al. “Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial..” In Prostate, 77:385–95, 2017. https://doi.org/10.1002/pros.23277.
    Full Text Link to Item
  - Choueiri, T. K., S. Halabi, B. Sanford, O. Hahn, M. D. Michaelson, M. Walsh, T. Olencki, et al. “CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial.” In Annals of Oncology, Vol. 27. Oxford University Press (OUP), 2016. https://doi.org/10.1093/annonc/mdw435.23.
    Full Text
  - Xie, W., C. Sweeney, M. Regan, M. Nakabayashi, M. Buyse, N. Clarke, L. Collette, et al. “Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP).” In Annals of Oncology, Vol. 27. OXFORD UNIV PRESS, 2016. https://doi.org/10.1093/annonc/mdw372.1.
    Full Text Link to Item
  - Patel, Jai N., Chen Jiang, Kouros Owzar, Daniel L. Hertz, Flora A. Mulkey, William K. Kelly, Susan Halabi, et al. “Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance).” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2016. https://doi.org/10.1158/1538-7445.am2016-2037.
    Full Text
  - Armstrong, A. J., S. Halabi, P. Healy, W. R. Lee, B. F. Koontz, J. W. Moul, K. Mundy, et al. “A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy..” In Prostate Cancer Prostatic Dis, 19:100–106, 2016. https://doi.org/10.1038/pcan.2015.59.
    Full Text Link to Item
  - George, Daniel J., Susan Halabi, Patrick Healy, Sarah Gemberling, Carolyn Winters, Kelly Mundy, Michael Roger Harrison, Russell Zelig Szmulewitz, and Andrew J. Armstrong. “Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC)..” In Journal of Clinical Oncology, 34:275–275. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.275.
    Full Text
  - Armstrong, Andrew J., Samuel Broderick, Tim Eisen, Walter Michael Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, et al. “Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Scher, Howard I., Michael J. Morris, Walter Michael Stadler, Celestia S. Higano, Susan Halabi, Matthew Raymond Smith, Ethan M. Basch, et al. “The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC)..” In Journal of Clinical Oncology, 33:5000–5000. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.5000.
    Full Text
  - Patel, Jai N., Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, et al. “Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE).” In Clinical Research (Excluding Clinical Trials). American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-3841.
    Full Text
  - Halabi, Susan, William Kevin Kelly, Haojin Zhou, Andrew J. Armstrong, David Quinn, Karim Fizazi, Nicole C. Solomon, et al. “The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials..” In Journal of Clinical Oncology, 32:5002–5002. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5002.
    Full Text
  - Hertz, Daniel Louis, Chen Jiang, Kouros Owzar, Susan Halabi, William Kevin Kelly, Flora Mulkey, Jai Narendra Patel, et al. “A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance)..” In Journal of Clinical Oncology, 32:9612–9612. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.9612.
    Full Text
  - Kluger, Harriet M., Susan Halabi, Nicole C. Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, and Daniel J. George. “Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206..” In Journal of Clinical Oncology, 32:4532–4532. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4532.
    Full Text
  - Patel, Jai Narendra, Chen Jiang, Daniel Louis Hertz, Flora Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, et al. “Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE)..” In Journal of Clinical Oncology, 32:e16061–e16061. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16061.
    Full Text
  - Halabi, S., C. Y. Lin, W. K. Kelly, K. Fizazi, J. W. Moul, E. Kaplan, M. J. Morris, and E. J. Small. “A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer.” In European Journal of Cancer, 49:S679–S679. ELSEVIER SCI LTD, 2013.
    Link to Item
  - Armstrong, Andrew J., Susan Halabi, Tim Eisen, Walter Michael Stadler, Robert R. Jones, Ultra N. Vaishampayan, Jorge A. Garcia, et al. “ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Bitting, Rhonda Lynn, Patrick Healy, Susan Halabi, Daniel J. George, Jung Hyun Ko, and Andrew J. Armstrong. “Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC)..” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Halabi, Susan, Chen-Yen Lin, Eric Jay Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Peter Petrylak, Cora N. Sternberg, et al. “A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Hertz, Daniel Louis, Kouros Owzar, Susan Halabi, William Kevin Kelly, Hitoshi Zembutsu, Chen Jiang, Jai Narendra Patel, et al. “A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Mahar, Alyson L., Susan Halabi, Lisa M. McShane, Patricia A. Groome, and Carolyn C. Compton. “A survey of clinical prediction took in colorectal and lung cancers and melanoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Nixon, Andrew B., Susan Halabi, Ivo Shterev, Mark Starr, John C. Brady, Janice P. Dutcher, Judith O. Hopkins, et al. “Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda Lynn Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer..” In Journal of Clinical Oncology, 31:105–105. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.105.
    Full Text
  - Halabi, Susan, Chen-Yen Lin, Eric Jay Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Peter Petrylak, Cora N. Sternberg, et al. “A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.24.
    Full Text Link to Item
  - Smith, Matthew Raymond, Susan Halabi, Charles J. Ryan, Walter Michael Stadler, Arif Hussain, Nicholas J. Vogelzang, Ralph J. Hauke, Ben L. Sanford, and Eric Jay Small. “Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)..” In Journal of Clinical Oncology, 31:27–27. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.27.
    Full Text
  - Apolo, Andrea Borghese, George Philips, Irina Ostrovnaya, Jonathan E. Rosenberg, Matthew I. Milowsky, Eric Jay Small, Dean F. Bajorin, and Susan Halabi. “External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy..” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Halabi, Susan, Andrew J. Armstrong, A Oliver Sartor, Johann Sebastian De Bono, Ellen B. Kaplan, and Eric Jay Small. “Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Kelly, William Kevin, Susan Halabi, Michael Anthony Carducci, Daniel J. George, John Francis Mahoney, Walter Michael Stadler, Michael J. Morris, Philip W. Kantoff, J. P. Monk, and Eric Jay Small. “Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)..” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Small, Eric Jay, Susan Halabi, Michael Anthony Carducci, Charles J. Ryan, Daniel J. George, John Francis Mahoney, Walter Michael Stadler, et al. “The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Halabi, Susan, William Kevin Kelly, Ellen B. Kaplan, and Eric Jay Small. “Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)..” In Journal of Clinical Oncology, 30:200–200. American Society of Clinical Oncology (ASCO), 2012. https://doi.org/10.1200/jco.2012.30.5_suppl.200.
    Full Text
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium..” In Journal of Clinical Oncology, 29:4664–4664. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.4664.
    Full Text
  - Hurwitz, M., S. Halabi, L. Archer, L. S. McGinnis, M. R. Kuettel, S. J. DiBiase, and E. J. Small. “Combination External Beam Radiation and Brachytherapy Boost with Androgen Suppression for Treatment of Intermediate-risk Prostate Cancer: Long-term Results of CALGB 99809.” In International Journal of Radiation Oncology*Biology*Physics, 78:S146–S146. Elsevier BV, 2010. https://doi.org/10.1016/j.ijrobp.2010.07.362.
    Full Text
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Armstrong, A. J., S. Halabi, I. F. Tannock, D. J. George, R. Dewit, and M. Eisenberger. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Halabi, S., O. Sartor, D. Petrylak, C. N. Sternberg, J. A. Witjes, M. Noursalehi, T. J. McKearn, and M. J. George. “Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Luu, T., O. Sartor, N. Dandade, S. Halabi, and C. Bennett. “Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Rini, B. I., S. Halabi, J. Rosenberg, W. M. Stadler, D. A. Vaena, J. N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E. J. Small. “Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - D’Amico, A. V., S. Halabi, R. Vollmer, M. Loffredo, E. McMahon, B. Sanford, L. Archer, N. J. Vogelzang, E. Small, and P. Kantoff. “p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study.” In International Journal of Radiation Oncology*Biology*Physics, 69:S333–S333. Elsevier BV, 2007. https://doi.org/10.1016/j.ijrobp.2007.07.1406.
    Full Text
  - D’Amico, A. V., S. Halabi, C. Tempany, R. Vollmer, M. Loffredo, B. Sanford, and E. J. Small. “Changes on endorectal MRI during neoadjuvant hormonal therapy for prostate cancer and biochemical outcome in men managed using radiation therapy: A prospective phase II Cancer and Leukemia Group B study.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Halabi, S., S. Ou, N. J. Vogelzang, H. Scher, and E. J. Small. “A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Scher, H. I., S. Halabi, I. Tannock, M. Morris, C. Higano, W. Kelly, C. Sternberg, M. Eisenberger, A. Martin, and M. Hussain. “The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Hurwitz, M. D., S. Halabi, S. S. Ou, L. S. McGinnis, M. R. Keuttel, S. J. DiBiase, and E. J. Small. “2230.” In International Journal of Radiation Oncology*Biology*Physics, 66:S337–38. Elsevier BV, 2006. https://doi.org/10.1016/j.ijrobp.2006.07.636.
    Full Text
  - Halabi, S., S. Ou, N. J. Vogelzang, and E. J. Small. “An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC)..” In Journal of Clinical Oncology, 24:230S-230S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Philips, G., B. Sanford, S. Halabi, D. Bajorin, and E. J. Small. “Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102..” In Journal of Clinical Oncology, 24:236S-236S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Picus, J., S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang. “Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782..” In Journal of Clinical Oncology, 24:234S-234S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Rosenberg, J. E., S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. Hohl, S. L. Seagren, D. F. Bajorin, and E. J. Small. “CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC)..” In Journal of Clinical Oncology, 24:237S-237S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Sartor, O., C. L. Bennett, S. Halabi, M. Kattan, and P. Scardino. “Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry..” In Journal of Clinical Oncology, 24:246S-246S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Schildkraut, Joellen M., Amy French, Brian Calingaert, Rex C. Bentley, Susan Murphy, Jeffrey R. Marks, Patricia Moorman, Susan Halabi, and Andrew Berchuck. “Molecular epidemiology of cyclin E overexpression in epithelial ovarian cancer.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.
    Link to Item
  - Dawson, N. A., S. Halabi, D. D. Biggs, S. S. Ou, W. K. Kelly, and E. J. Small. “A phase II study of estramustine (E), docetaxel (D) and exisulind in hormonerefractory prostate cancer (HRPC): Initial results of CALGB 90004..” In Journal of Clinical Oncology, 23:415S-415S. AMER SOC CLINICAL ONCOLOGY, 2005.
    Link to Item
  - Garber, J. E., S. Halabi, E. Kaplan, S. Edge, L. Dressler, E. Paskett, and N. Berliner. “Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen..” In Journal of Clinical Oncology, 23:6S-6S. AMER SOC CLINICAL ONCOLOGY, 2005.
    Link to Item
  - Halabi, S., E. J. Small, S. Ou, and N. J. Vogelzang. “The impact of age on clinical outcomes in men with hormone refractory prostate cancer.” In Journal of Clinical Oncology, 23:408S-408S. AMER SOC CLINICAL ONCOLOGY, 2005.
    Link to Item
  - Rini, B. I., S. Halabi, R. Barrier, K. A. Margolin, D. Avigan, T. Logan, P. L. McCarthy, E. S. Small, and C. A. Linker. “CALGB 90003: Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: An intergroup phase II study.” In Blood, 104:231A-231A. AMER SOC HEMATOLOGY, 2004.
    Link to Item
  - Schildkraut, J. M., A. Berchuck, S. Murphy, J. Marks, P. Moorman, B. Calingaert, and S. Halabi. “Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer..” In Cancer Epidemiology Biomarkers & Prevention, 13:1897S-1897S. AMER ASSOC CANCER RESEARCH, 2004.
    Link to Item
  - D’Amico, A. V., S. Halabi, N. J. Vogelzang, and E. J. Small. “A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.” In Journal of Clinical Oncology, 22:383S-383S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Halabi, S., E. J. Small, T. Gilligian, R. Barrier, S. George, and N. J. Vogelzang. “The effect of race on progression-free survival in patients with metastatic hormone-refractory prostate cancer (HRPC): A pooled analysis of CALGB studies..” In Journal of Clinical Oncology, 22:400S-400S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Humphrey, P., S. Halabi, J. Picus, N. Vogelzang, E. Small, and P. Kantoff. “Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480..” In Journal of Clinical Oncology, 22:863S-863S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Philips, G., S. Halabi, B. Sanford, D. Bajorin, and E. Small. “Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102..” In Journal of Clinical Oncology, 22:391S-391S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Picus, J., S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang. “Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782..” In Journal of Clinical Oncology, 22:396S-396S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Ryan, C. H., S. Halabi, E. Kaplan, N. Vogelzang, P. Kantoff, and E. J. Small. “Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583..” In Journal of Clinical Oncology, 22:396S-396S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Stadler, W. M., S. Halabi, M. S. Ernstoff, R. Barrier, E. Davila, J. Picus, and E. J. Small. “A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008..” In Journal of Clinical Oncology, 22:385S-385S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Taplin, M. E., D. J. George, S. Halabi, W. R. Sellers, B. Sanford, K. T. Hennessy, G. G. Mihos, E. J. Small, and P. W. Kantoff. “Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated an Cancer and Leukemia Group B (CALGB) 9480..” In Journal of Clinical Oncology, 22:396S-396S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Schildkraut, J. M., R. Wenham, J. Lancaster, B. Calingaert, K. McLean, S. Halabi, J. Marks, and A. Berchuck. “A case-control study of candidate ovarian cancer susceptibility polymorphisms..” In Cancer Epidemiology Biomarkers & Prevention, 11:1165S-1165S. AMER ASSOC CANCER RESEARCH, 2002.
    Link to Item
Teaching & Mentoring
Recent Courses
- CRP 248: Clinical Trials 2018

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

In the News

Awards & Honors

Subject Headings

Global Scholarship

Research

Selected Grants

Selected Publications

Academic Articles

Conference Papers

Recent Courses